Literature DB >> 16244578

Identification of novel binding partners for tuberous sclerosis complex 2 (TSC2) by yeast two-hybrid approach.

O M Malanchuk1, V Pozur, G G Panasyuk, I O Nemazanyy, V V Filonenko, I T Gout, S S Palchevskyy.   

Abstract

AIM: To identify novel tuberous sclerosis complex (TSC2) binding partners by yeast two-hybrid screening.
METHODS: The yeast two-hybrid system DupLEX-A developed by OriGene Technologies and Mouse embryo and HeLa cells cDNA libraries were used in this study. The "bait" constructs, containing full-length and truncated form of TSC2 were prepared. The expression of all constructs in yeast was confirmed by immunoblotting with specific anti-LexA antibodies. The suitability of generated constructs for screening was tested in autoactivation and nuclear translocation assays. Screening of mouse embryo and HeLa cDNA libraries with selected baits was carried out according to manufacturer's recommendations. Positive clones were selected using double selection procedure and further confirmed in mating assay. Isolated cDNA clones were identified by automated DNA sequencing and database searching.
RESULTS: Extensive screening of two cDNA libraries from mouse embryo and HeLa cells with TSC2 baits led to the isolation of 102 positives clones. The specificity of interaction between TSC2 and binding proteins of selected clones was confirmed by mating assay for 83 clones. Sequencing of these clones indicated that they encode already known and novel TSC2-binding partners.
CONCLUSION: The isolation of several known TSC2-binding partners, such as several isoforms of 14-3-3, demonstrates the validity of generated bait constructs and screening conditions. In addition, we have found a number of novel interactors, which encode cytoskeletal proteins and signaling molecules, such as Ser/Thr phosphatases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16244578

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  1 in total

1.  Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth.

Authors:  Fayi Wu; Stephanie O Peacock; Shuyun Rao; Sandra K Lemmon; Kerry L Burnstein
Journal:  J Biol Chem       Date:  2012-12-31       Impact factor: 5.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.